Wang R, Zhu Y, Liu X, Liao X, He J, Niu L. The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer. 2019;19:1–12.
Foote RL, Weidner N, Harris J, Hammond E, Lewis JE, Vuong T, et al. Evaluation of tumor angiogenesis measured with microvessel density (MVD) as a prognostic indicator in nasopharyngeal carcinoma: results of RTOG 9505. Int J Radiat Oncol Biol Phys. 2005;61:745–53.
Bais C, Mueller B, Brady MF, Mannel RS, Burger RA, Wei W, et al. Tumor microvessel density as a potential predictive marker for bevacizumab benefit: GOG-0218 biomarker analyses. J Natl Cancer Inst. 2017;109:djx066.
Article PubMed PubMed Central Google Scholar
Mucci LA, Powolny A, Giovannucci E, Liao Z, Kenfield SA, Shen R, et al. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol. 2009;27:5627.
Article PubMed PubMed Central Google Scholar
Krock BL, Skuli N, Simon MC. Hypoxia-induced angiogenesis: good and evil. Genes Cancer. 2011;2:1117–33.
Article PubMed PubMed Central Google Scholar
Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti-and pro-angiogenic therapies. Genes Cancer. 2011;2:1097–105.
Article PubMed PubMed Central Google Scholar
Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17:471–94.
Article CAS PubMed PubMed Central Google Scholar
Abbas W, Kumar A, Herbein G. The eEF1A proteins: at the crossroads of oncogenesis, apoptosis, and viral infections. Front Oncol. 2015;5:75.
Article PubMed PubMed Central Google Scholar
Anand N, Murthy S, Amann G, Wernick M, Porter LA, Cukier IH, et al. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet. 2002;31:301–5.
Article CAS PubMed Google Scholar
Cao H, Zhu Q, Huang J, Li B, Zhang S, Yao W, et al. Regulation and functional role of eEF1A2 in pancreatic carcinoma. Biochem Biophys Res Commun. 2009;380:11–6.
Article CAS PubMed Google Scholar
Pellegrino R, Calvisi DF, Neumann O, Kolluru V, Wesely J, Chen X, et al. EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR‐dependent stabilization of MDM4 in hepatocellular carcinoma. Hepatology. 2014;59:1886–99.
Article CAS PubMed Google Scholar
Kulkarni G, Turbin DA, Amiri A, Jeganathan S, Andrade-Navarro MA, Wu TD, et al. Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer. Breast Cancer Res Treat. 2007;102:31–41.
Article CAS PubMed Google Scholar
Hassan MK, Kumar D, Patel SA, Dixit M. EEF1A2 triggers stronger ERK mediated metastatic program in ER negative breast cancer cells than in ER positive cells. Life Sci. 2020;262:118553.
Article CAS PubMed Google Scholar
Knowles HJ, Cleton-Jansen A, Korsching E, Athanasou NA. Hypoxia‐inducible factor regulates osteoclast‐mediated bone resorption: role of angiopoietin‐like 4. FASEB J. 2010;24:4648–59.
CAS PubMed PubMed Central Google Scholar
Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002;1:237–46.
Article CAS PubMed Google Scholar
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281–308.
Article CAS PubMed PubMed Central Google Scholar
Kumar D, Patel SA, Khan R, Chawla S, Mohapatra N, Dixit M. IQ Motif-containing GTPase-activating protein 2 inhibits breast cancer angiogenesis by suppressing VEGFR2–AKT signaling. Mol Cancer Res. 2022;20:77–91.
Article CAS PubMed Google Scholar
Naik M, Brahma P, Dixit M. A cost-effective and efficient chick ex-ovo CAM assay protocol to assess angiogenesis. Methods Protoc. 2018;1:19.
Article CAS PubMed PubMed Central Google Scholar
Rio DC, Ares M, Hannon GJ, Nilsen TW. Purification of RNA using TRIzol (TRI reagent). Cold Spring Harb Protoc. 2010;2010:pdb-prot5439.
Kang H. Sample size determination and power analysis using the G* Power software. J Educ Eval Health Prof. 2021;18:17.
Article PubMed PubMed Central Google Scholar
De Francesco EM, Lappano R, Santolla MF, Marsico S, Caruso A, Maggiolini M. HIF-1α/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). Breast Cancer Res. 2013;15:1–18.
Wang Y, Yang C, Gu Q, Sims M, Gu W, Pfeffer LM, et al. KLF4 promotes angiogenesis by activating VEGF signaling in human retinal microvascular endothelial cells. PLoS One. 2015;10:e0130341.
Article PubMed PubMed Central Google Scholar
Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5:378–89.
Article PubMed PubMed Central Google Scholar
Wang X, Bove AM, Simone G, Ma B. Molecular bases of VEGFR-2-mediated physiological function and pathological role. Front Cell Dev Biol. 2020;8:599281.
Article PubMed PubMed Central Google Scholar
Doe MR, Ascano JM, Kaur M, Cole MD. Myc posttranscriptionally induces HIF1 protein and target gene expression in normal and cancer cells. Cancer Res. 2012;72:949–57.
Article CAS PubMed Google Scholar
Lee T, Yao G, Nevins J, You L. Sensing and integration of Erk and PI3K signals by Myc. PLoS Comput Biol. 2008;4:e1000013.
Article PubMed PubMed Central Google Scholar
Dodd KM, Yang J, Shen MH, Sampson JR, Tee AR. mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene. 2015;34:2239–50.
Article CAS PubMed Google Scholar
Xu C, Hu D, Zhu Q. eEF1A2 promotes cell migration, invasion and metastasis in pancreatic cancer by upregulating MMP-9 expression through Akt activation. Clin Exp Metastasis. 2013;30:933–44.
Worst TS, Waldbillig F, Abdelhadi A, Weis C-A, Gottschalt M, Steidler A, et al. The EEF1A2 gene expression as risk predictor in localized prostate cancer. BMC Urol. 2017;17:1–9.
Jia L, Ge X, Du C, Chen L, Zhou Y, Xiong W, et al. EEF1A2 interacts with HSP90AB1 to promote lung adenocarcinoma metastasis via enhancing TGF-β/SMAD signalling. Br J Cancer. 2021;124:1301–11.
Article CAS PubMed PubMed Central Google Scholar
Losada A, Muñoz-Alonso MJ, Martínez-Díez M, Gago F, Domínguez JM, Martínez-Leal JF, et al. Binding of eEF1A2 to the RNA-dependent protein kinase PKR modulates its activity and promotes tumour cell survival. Br J Cancer. 2018;119:1410–20.
Article CAS PubMed PubMed Central Google Scholar
Jun JC, Rathore A, Younas H, Gilkes D, Polotsky VY. Hypoxia-inducible factors and cancer. Curr Sleep Med Rep. 2017;3:1–10.
Article PubMed PubMed Central Google Scholar
Lee Y-H, Bae HC, Noh KH, Song K-H, Ye S, Mao C-P, et al. Gain of HIF-1α under normoxia in cancer mediates immune adaptation through the AKT/ERK and VEGFA AxesHIF-1α mediates cancer immune adaptation. Clin Cancer Res. 2015;21:1438–46.
Article CAS PubMed PubMed Central Google Scholar
Yang J, Tang J, Li J, Cen Y, Chen J, Dai G. Effect of activation of the Akt/mTOR signaling pathway by EEF1A2 on the biological behavior of osteosarcoma. Ann Transl Med. 2021;9:158.
Article CAS PubMed PubMed Central Google Scholar
Li Z, Qi C-F, Shin D-M, Zingone A, Newbery HJ, Kovalchuk AL, et al. Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas. PLoS One. 2010;5:e10755.
Article PubMed PubMed Central Google Scholar
Tsai W-B, Aiba I, Long Y, Lin H-K, Feun L, Savaraj N, et al. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Res. 2012;72:2622–33.
Article CAS PubMed PubMed Central Google Scholar
Nilsson M, Heymach JV. Vascular endothelial growth factor (VEGF) pathway. J Thorac Oncol. 2006;1:768–70.
Comments (0)